Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:OBLN

Obalon Therapeutics (OBLN) Stock Price, News & Analysis

Obalon Therapeutics logo

About Obalon Therapeutics Stock (NASDAQ:OBLN)

Key Stats

Today's Range
$4.28
$4.69
50-Day Range
$2.36
$7.64
52-Week Range
$0.66
$10.77
Volume
41,464 shs
Average Volume
7.68 million shs
Market Capitalization
$43.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity. The company offers the Obalon Balloon System designed to provide weight loss in patients with obesity. Its Obalon Balloon System comprises of a swallowable capsule that contains an inflatable balloon attached to a microcatheter; the Obalon Navigation System console, which is a combination of hardware and software used to track and display the location of the balloon during placement; the Obalon Touch Inflation Dispenser, which is a semi-automated, hand-held inflation device used to inflate the balloon once it is placed; and a disposable canister filled with mixture of gas. Obalon Therapeutics, Inc. was incorporated in 2008 and is headquartered in Carlsbad, California.

Receive OBLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Obalon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

OBLN Stock News Headlines

Obalon Therapeutics, Inc.
How to piss off your liberal friends… and profit from it
Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.
Spero Therapeutics Inc.
Renovare Environmental Inc (RENO)
See More Headlines

OBLN Stock Analysis - Frequently Asked Questions

Obalon Therapeutics, Inc. (NASDAQ:OBLN) announced its quarterly earnings results on Thursday, March, 11th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by $0.11. The business earned $0.06 million during the quarter. Obalon Therapeutics had a negative net margin of 776.76% and a negative trailing twelve-month return on equity of 161.38%.

Obalon Therapeutics shares reverse split on the morning of Thursday, July 25th 2019. The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 24th 2019. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Obalon Therapeutics (OBLN) raised $75 million in an initial public offering on Thursday, October 6th 2016. The company issued 5,000,000 shares at $14.00-$16.00 per share. UBS Investment Bank, Canaccord Genuity and Stifel served as the underwriters for the IPO and BTIG was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Obalon Therapeutics investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Canopy Growth (CGC), Plug Power (PLUG), NIO (NIO), NVIDIA (NVDA) and OPKO Health (OPK).

Company Calendar

Last Earnings
3/11/2021
Today
12/22/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & Medical Instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:OBLN
Fax
N/A
Employees
2
Year Founded
2008

Profitability

Net Income
$-12,330,000.00
Net Margins
-776.76%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.59 million
Book Value
$0.60 per share

Miscellaneous

Free Float
N/A
Market Cap
$43.90 million
Optionable
Not Optionable
Beta
-1.23

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:OBLN) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners